DE3585093D1 - Tumorspezifische monoklonale antikoerper. - Google Patents

Tumorspezifische monoklonale antikoerper.

Info

Publication number
DE3585093D1
DE3585093D1 DE8585300610T DE3585093T DE3585093D1 DE 3585093 D1 DE3585093 D1 DE 3585093D1 DE 8585300610 T DE8585300610 T DE 8585300610T DE 3585093 T DE3585093 T DE 3585093T DE 3585093 D1 DE3585093 D1 DE 3585093D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
tumor
specific monoclonal
relates
diagnostic procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585300610T
Other languages
English (en)
Inventor
G Hanna
Martin V Haspel
Hoover, Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INTRACEL NETHERLANDS, B.V., AMSTERDAM, NL
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24300700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3585093(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of DE3585093D1 publication Critical patent/DE3585093D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE8585300610T 1984-01-31 1985-01-30 Tumorspezifische monoklonale antikoerper. Expired - Lifetime DE3585093D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57553384A 1984-01-31 1984-01-31

Publications (1)

Publication Number Publication Date
DE3585093D1 true DE3585093D1 (de) 1992-02-20

Family

ID=24300700

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585300610T Expired - Lifetime DE3585093D1 (de) 1984-01-31 1985-01-30 Tumorspezifische monoklonale antikoerper.

Country Status (15)

Country Link
EP (1) EP0151030B1 (de)
JP (2) JPH0759518B2 (de)
AT (1) ATE71410T1 (de)
AU (2) AU589351B2 (de)
CA (1) CA1340781C (de)
DE (1) DE3585093D1 (de)
DK (1) DK171896B1 (de)
ES (1) ES8802621A1 (de)
GR (1) GR850179B (de)
HU (1) HU209519B (de)
IE (1) IE58859B1 (de)
IL (1) IL74156A (de)
NZ (1) NZ210867A (de)
PT (1) PT79894B (de)
ZA (1) ZA85689B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3319751A1 (de) * 1983-05-31 1984-12-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren zur gewinnung von gegen tumorantigene gerichteten monoklonalen antikoerpern und diese enthaltende arzneimittel
US6294172B1 (en) 1983-08-12 2001-09-25 Dade Behring Marburg Gmbh Monoclonal antibodies with specificity for membrane-associated antigens
DE3629640A1 (de) * 1986-08-30 1988-03-03 Behringwerke Ag Verwendung monoklonaler antikoerper zur therapie von tumoren
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5552291A (en) * 1985-10-09 1996-09-03 Kyowa, Hakko Kogyo Co., Ltd. Anti-human pulmonary adenocarcinoma specific monoclonal antibody
JPS6283898A (ja) * 1985-10-09 1987-04-17 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺腺癌特異的単クロ−ン性抗体
EP0222360A3 (de) * 1985-11-12 1989-03-15 Biotherapeutics Inc. Verfahren zur Herstellung von einem patientspezifischen zytotoxischen Reagenz und Zubereitung
JPS62207298A (ja) * 1986-03-06 1987-09-11 Kyowa Hakko Kogyo Co Ltd 抗ヒト胃癌単クロ−ン性抗体
JPH06100843B2 (ja) * 1986-06-23 1994-12-12 キヤノン株式会社 絶縁性磁性乾式現像剤
EP0265156A3 (de) * 1986-10-14 1990-08-29 Bunge (Australia) Proprietary Limited Monoklonale Antikörper
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
AU618209B2 (en) * 1987-07-02 1991-12-12 Akzo N.V. Antigen recognized by mca 16-88
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
WO1990015625A1 (en) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPY USING α-PARTICLES EMISSION
CA2079601A1 (en) * 1990-04-12 1991-10-13 Nicholas Pomato Ctaa 28a32, the antigen recognized by mca 28a32
CA2086531A1 (en) * 1990-07-03 1992-01-04 Ebo S. Bos Immunoreactive compound
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
WO1992020785A1 (en) * 1991-05-16 1992-11-26 Akzo N.V. Tumor associated monoclonal antibody 81av78
IL103758A (en) * 1991-12-13 1998-07-15 Akzo Nv Cancer-specific monoclonal antibodies
JPH06113831A (ja) * 1992-04-08 1994-04-26 Dev Center For Biotechnol ハイブリドーマおよびその抗体
EP0650735A3 (de) * 1993-07-09 1999-04-14 Akzo Nobel N.V. Kit und Verfahren zum Vorziehen
WO2003072032A2 (en) 2002-02-22 2003-09-04 Intracel Resources Llc Sterile immunogenic non-tumorigenic tumor cell compositions and methods
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
WO2015049688A2 (en) * 2013-10-02 2015-04-09 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors
EP3409297A1 (de) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. Optimaler 225actinium-213bismut-generator für alpha-partikelradioimmunotherapie
US20200230266A1 (en) 2017-09-20 2020-07-23 Alfarim Medical Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4322879A (en) * 1978-01-11 1979-07-19 Massachusetts General Hospital, The Producing antibodies
DE3211356A1 (de) * 1982-03-27 1983-09-29 Behringwerke Ag, 3550 Marburg Zell-hybrid, verfahren zu seiner herstellung sowie seine verwendung
JPS58201994A (ja) * 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
JPS59137497A (ja) * 1983-01-20 1984-08-07 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・カリフオルニア 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells

Also Published As

Publication number Publication date
GR850179B (de) 1985-05-23
HUT36859A (en) 1985-10-28
ES539987A0 (es) 1988-09-16
JPH06315395A (ja) 1994-11-15
NZ210867A (en) 1989-01-06
JPS60260597A (ja) 1985-12-23
DK40885D0 (da) 1985-01-30
EP0151030A3 (en) 1987-11-25
IL74156A (en) 1990-08-31
CA1340781C (en) 1999-10-12
HU209519B (en) 1994-06-28
EP0151030A2 (de) 1985-08-07
JPH0759518B2 (ja) 1995-06-28
JP2516731B2 (ja) 1996-07-24
ATE71410T1 (de) 1992-01-15
ZA85689B (en) 1986-04-30
IL74156A0 (en) 1985-04-30
IE58859B1 (en) 1993-11-17
AU4736789A (en) 1990-05-03
IE850192L (en) 1985-07-31
AU3799285A (en) 1985-08-08
EP0151030B1 (de) 1992-01-08
PT79894B (en) 1986-10-23
PT79894A (en) 1985-02-01
DK171896B1 (da) 1997-08-04
DK40885A (da) 1985-10-25
AU589351B2 (en) 1989-10-12
ES8802621A1 (es) 1988-09-16
AU635511B2 (en) 1993-03-25

Similar Documents

Publication Publication Date Title
DE3585093D1 (de) Tumorspezifische monoklonale antikoerper.
ZA833686B (en) Human human hybridomas for cervical carcinoma
KR880700061A (ko) 인체 암종양과 관련된 항원에 대한 단클론성 항체
ATE71225T1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.
DE68924983D1 (de) Anti-idiotyp antikörper induktion eines antitumorenresponses.
EP0328578A4 (de) Von mca 16-88 erkanntes antigen.
FI935038A (fi) Tumoer associerad monoklonal antikropp 81av78
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
Ferrone et al. Active Specific Immunotherapy of Malignant Melanoma with Anti‐idiotypic Monoclonal Antibodies
DE3784364D1 (de) Tumorassoziiertes antigen.
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AKZO NOBEL N.V., ARNHEIM/ARNHEM, NL

8327 Change in the person/name/address of the patent owner

Owner name: INTRACEL NETHERLANDS, B.V., AMSTERDAM, NL

8328 Change in the person/name/address of the agent

Free format text: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAELTE, 81541 MUENCHEN